Merck & Co., Inc. is hoping to be at the head of the TIGIT field, seen by many as the most promising class in the new wave of immuno-oncology products and currently led by Roche Holding AG's tiragolumab, and early stage data on its candidate, vibostolimab, while limited, look promising.
ESMO: Merck & Co Vibostolimab Data Are Another Validation Of TIGIT
Shows Promise Alone And In Keytruda Combo
A number of anti-TIGIT drugs are jockeying for position to provide benefit as monotherapies and in combinations for non-small cell lung cancer and Merck's offering is looking to challenge Roche's tiragolumab for the lead.
